At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 70 enrolled
Drug / intervention
ribavirin +2 moredrug
Likely dose
ribavirin 200 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Trial of CTS-1027 in Interferon-Naive Hepatitis C Patients
In Brief
A Phase 2 clinical trial evaluating ribavirin, CTS-1027, and 1 other intervention for Hepatitis C. Completed, enrolled 70 participants across 21 sites in 2 countries.
Detailed Summary
The study is intended to determine whether CTS-1027 either alone or in combination with ribavirin is safe and effective in Hepatitis C patients who have not previously been treated with interferon.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHepatitis C
CountriesPuerto Rico, United States
Collaborators--
Timeline
Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartJun 2009
First PostedJun 2009
Primary CompletionMay 2010
Study CompletionJul 2010
TodayJul 2026
First PostedJun 23, 2009
Enrollment StartJun 1, 2009
Primary CompletionMay 1, 2010
Study CompletionJul 1, 2010
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 17.0 years ago
Interventions
ribavirindrug
200 mg capsules, either 1000 or 1200 mg taken twice daily for up to 24 weeks
CTS-1027drug
5 and 10 mg tablets, 15 mg taken twice daily, for up to 24 weeks
Placebo for ribavirindrug
Capsules identical to ribavirin in appearance containing inactive ingredients